History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Cycle for Survival Fred's Team Rock & Run on the River Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck CELEBRATIONS
Press Releases In the News Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days IS Careers Job Search & Apply Online
Making an Appointment

A Phase II Trial of Nonmyeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies

[Protocol 09-084]

Full Title :
A MULTI-CENTER, PHASE II TRIAL OF NONMYELOABLATIVE CONDITIONING (NST) AND TRANSPLANTATION OF PARTIALLY HLA-MISMATCHED BONE MARROW FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES (BMT CTN PROTOCOL 0603)
Purpose :

Stem cell transplantation is often used to treat cancers of the blood and lymph glands. Ideally it is best to give the patient stem cells from a completely matched donor, such as a relative with the same tissue type. But not all patients have perfectly matched donors readily available, and their disease may worsen in the time it takes to find one.

The purpose of this study is to determine whether a reduced intensity transplant (sometimes referred to as a "nonmyeloablative transplant") from partially mismatched donors is a safe and effective treatment for patients with blood and lymphatic cancers. This new transplant does not use high doses of chemotherapy or radiation therapy.

This regimen is being assessed in patients for whom there are no known curative therapies outside of a stem cell transplant and who do not have a matched donor.

Eligibility :

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have acute leukemia or Burkitt's lymphoma in second or greater remission, or another form of lymphoma which persists despite prior therapy.
  • Patients must not have a matched stem cell donor available.
  • Patients must have received chemotherapy within three months of entering the study.
  • Donors must be HLA-haploidentical first-degree relatives of the patient (including sibling, parents, children, or half-siblings).
  • Patients must be between the ages of 21 and 70, and donors must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Miguel-Angel Perales at 212-639-8682.

Back to All Clinical Trials
Bookmark and SharePrintEmail This Page